The Scale Is Moving. What Are You Protecting?

The part the scale cannot tell you

Do you lose muscle on semaglutide or tirzepatide?

Yes, some. GLP-1-based medicines can produce meaningful weight loss, and in the body-composition substudies of the STEP 1 semaglutide trial and the SURMOUNT-1 tirzepatide trial most of the measured loss was fat, but lean mass also declined. “Lean mass” includes more than muscle (water, organs and other non-fat tissue), and a scan does not tell us whether your strength or function changed.

Lighter is not the same as stronger. The goal is not to fear the medicine. It is to make the weight-loss plan intelligent enough to protect what matters. In practice that means asking four questions alongside the number on the scale:

• Can I still meet my nutritional needs?
• Am I maintaining strength and function?
• Is the loss too fast for me?
• Do my symptoms require a medication review?

Those questions are built into every program on our GLP-1 weight-loss page.

The actual lean-mass plan

How do you preserve muscle on a GLP-1 medicine?

You preserve lean mass by running four lanes at the same time: adequate intake, individualized protein, progressive strength training and clinical follow-up. No single powder can replace that system. The plan works when nutrition, strength, medication care and measurement agree, which is the framework of the joint advisory on nutritional priorities for GLP-1 therapy from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society.

1. Adequate intake. Review food, fluids, gastrointestinal symptoms, and whether reduced appetite is leaving important gaps. A shake cannot replace an entire diet.
2. Individualized protein. Professional guidance proposes 1.2–1.6 g/kg/day during active weight reduction, but the weight basis and the target must be individualized.
3. Progressive strength. When medically appropriate, resistance training supplies the signal that nutrition alone cannot. Guidance suggests at least three strength sessions weekly.
4. Clinical follow-up. Track tolerance, hydration, rate of loss, function, symptoms, and body composition only when the result will change management.

How much protein should you eat on a GLP-1?

The multi-society advisory proposes 1.2–1.6 g of protein per kg per day during active weight reduction, but it is not a universal dose. The appropriate weight basis can be uncertain in obesity, and kidney or liver conditions, pregnancy, how much food you can actually eat, tolerance and other clinical factors can change the plan. This is a number to set with your clinician or a registered dietitian, not to copy from a chart.

Is whey a bad protein choice?

No. Whey was the active, equal-protein comparator in the ProGo pilot, not a placebo. The study does not show that whey fails, that ProGo is best for every person, or that either powder is more important than adequate food and progressive resistance training.

The human study, without the sales layer

What did the ProGo study actually show?

In a 2026 double-blind pilot published in Biomedicines, seven people took 12 g a day of ProGo and seven took 12 g of whey for 56 days. The ProGo arm showed larger changes than whey on several paper-designated blood outcomes and on a self-reported hair, nail and skin satisfaction score. It is interesting precisely because whey was an active comparator, not a sugar pill. But fourteen people over 56 days cannot answer questions about muscle preservation, long-term safety, or use with GLP-1 medication.

What it found

Several designated blood outcomes and a subjective hair/nail/skin score favored ProGo. Body-composition, glucose and inflammatory results were exploratory, unadjusted for multiple comparisons, and need independent confirmation. The blood findings, including ferritin and hemoglobin, are covered in detail in my article on ferritin, hair and laser recovery.

What it did not test

• No semaglutide, tirzepatide, retatrutide or other GLP-1 users.
• No direct skeletal-muscle, strength or physical-function test. Fat-free mass was estimated indirectly by bioelectrical impedance (BIA) as an exploratory outcome.
• No human DPP-4, GLP-1, GIP or peptide-absorption measurement.
• No long-term, allergy, pregnancy, kidney or liver, or medication-interaction answer.

Who ran it

The ClinicalTrials.gov registry (NCT07616752) names Hofseth Biocare, the ingredient’s manufacturer, as sponsor. The paper discloses company employment, consulting or statistical collaboration among its authors. Independent replication matters. It is also worth knowing exactly what was studied: a named salmon protein hydrolysate. Generic marine peptides, fish collagen and lower-dose blends should not be assumed equivalent.

Four different levels of evidence

How strong is the evidence for ProGo and GLP-1 care?

Only one level is established care, and it is not the powder. The distance between a lab finding, a small pilot and a patient result is where hype usually grows, so it helps to see them side by side.

What about “natural GLP-1”?

Is ProGo a natural GLP-1 or an alternative to semaglutide?

No. A receptor assay is not a prescription drug. Specific salmon hydrolysates showed DPP-IV inhibition, glucose-tracer uptake, and GLP-1 receptor and GIP receptor reporter activity in laboratory systems, but the human pilot did not measure any of those pathways. ProGo has not been shown to replace, reproduce or strengthen a GLP-1 or GIP medicine, or to permit a dose reduction.

• Laboratory: a biological hypothesis. Cell-free enzymes, rat cells and engineered reporter lines can suggest where to look next.
• Human pilot: different measurements. The trial measured blood, self-report and exploratory body-composition and metabolic outcomes, not incretin pharmacology.
• Patient care: no medication equivalence. Do not replace, reduce or combine prescription treatment based on these laboratory findings.

How to evaluate a product without guessing

Where can I buy the ProGo used in the study?

We have not verified a current consumer product that clearly declares 12 g a day of authentic ProGo through an official purchase route. ProGo is documented as a manufacturer ingredient, and an ingredient page is not evidence that a finished product contains it at the studied dose. Before a product deserves the study’s name, it should pass four questions:

1. Does it name ProGo®? Not just salmon peptides, marine protein, fish collagen or a proprietary blend.
2. Does it state 12 g of ProGo® per daily use? Twelve grams of total protein or blend weight is not the same claim.
3. Can the package lot be documented? Ask for lot-linked identity, test methods, limits and actual results, not a generic quality badge.
4. Is the purchase route official and current? A marketplace listing or ingredient page does not prove finished-product identity or supply.

If any answer is “no” or “not sure,” the product is unverified. A self-check does not verify identity, dose, quality, safety, availability or authenticity; bring the package and current documents to a consultation and we will review them. If documentation is missing, our answer will be “not verified.” In the United States, dietary supplements are not approved by the FDA before sale, and manufacturing quality is governed by current good manufacturing practice rules (21 CFR Part 111), which is another reason lot documentation matters.

Book the plan, not the powder

What should a GLP-1 lean-mass review cover?

A useful review connects symptoms, intake, function, medication care and only the measurements that can change the plan. Here is how common concerns map to what we look at:

Programs are available virtually through telehealth, and the metabolic and biological-age baseline sits on our diagnostics page. For why muscle and metabolic fitness matter beyond the scale, see the FNIP1 metabolic fitness gene.

Frequently asked questions

Is ProGo a natural GLP-1 or an alternative to semaglutide or tirzepatide?

No. Laboratory studies of specific salmon hydrolysates are not human prescription-drug pharmacology. ProGo has not been shown to replace, reproduce, strengthen, or permit dose reduction of a GLP-1 or GIP medicine.

Does ProGo prevent muscle loss during GLP-1 treatment?

No study has shown that. The 14-person ProGo pilot excluded recent weight-loss-medication users, used an indirect BIA fat-free-mass estimate as an exploratory outcome, and did not measure skeletal muscle, strength or physical function directly.

Is whey a bad protein choice?

No. Whey was an active, equal-protein comparator in the pilot, not a placebo. The study does not show that whey fails, that ProGo is best for every person, or that either powder is more important than adequate food and progressive resistance training.

Where can I buy the same ProGo used in the study?

ProGo is verified as a manufacturer ingredient, but we have not verified a current consumer product that clearly declares 12 g/day of authentic ProGo through an official purchase route. We can review current labels and manufacturer documents, but a consultation is not an order, reservation or supply guarantee.

Can I use salmon peptides if I have a fish allergy?

Do not self-test a fish-derived supplement after a diagnosed or possible fish reaction. Hydrolysis does not prove allergy safety. Review the exact product with an allergist or treating clinician; urgent allergic symptoms require emergency care.

How much protein should I eat while using a GLP-1 medicine?

A multi-society advisory proposes 1.2–1.6 g/kg/day during active weight reduction, but it is not a universal dose and the appropriate weight basis can be uncertain in obesity. Kidney or liver conditions, pregnancy, food intake, tolerance and other clinical factors can change the plan.

Do I lose muscle on semaglutide or tirzepatide?

In body-composition substudies of STEP 1 and SURMOUNT-1, most of the weight lost was fat, but lean mass also declined. Lean mass includes more than muscle, and a scan does not show whether strength or function changed, which is why nutrition, protein, strength training and follow-up belong in the same plan.

Verifiable sources

The ProGo evidence is one 14-person, 56-day, company-sponsored pilot that excluded GLP-1 users, plus laboratory studies. The manufacturer source is not independent efficacy evidence.

• Currie C, Myklebust TÅ, Bjerknes C, Framroze B. A pilot study of salmon protein hydrolysate (ProGo®) supplementation to assess its impact on hematologic, integumentary and metabolic health. Biomedicines. 2026;14(8):1663. PMC
• ClinicalTrials.gov. NCT07616752: The impact of salmon protein hydrolysate supplementation on hematologic and metabolic health. Record and record history.
• Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of STEP 1. PMC
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Europe PMC
• American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. Nutritional priorities to support GLP-1 therapy for obesity: corrected joint advisory. PMC
• Bjerknes C, et al. Glucoregulatory properties of a protein hydrolysate from Atlantic salmon: DPP-IV inhibition and direct glucose uptake in vitro. PMC
• Currie C, et al. Initial exploration of in vitro activation of GLP-1 and GIP receptors and pancreatic islet cell protection by salmon-derived bioactive peptides. PMC
• Hofseth BioCare. ProGo® bioactive peptides. Manufacturer ingredient source; not independent efficacy evidence. hofsethbiocare.com
• U.S. Food and Drug Administration. Food allergies. fda.gov
• Jiang J, et al. Effect of processing on fish protein antigenicity and allergenicity. 2021. PMC
• U.S. Food and Drug Administration. FDA 101: dietary supplements. fda.gov
• Electronic Code of Federal Regulations. 21 CFR Part 111: Dietary supplement current good manufacturing practice. ecfr.gov